LRRK2 Antisense Oligonucleotide Therapies for Parkinson's Disease

Migration, Crosslink

📖

LRRK2 Antisense Oligonucleotide Therapies for Parkinson's Disease

active

wiki page Created: 2026-04-02T07:18:59 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-lrrk2-antisense-therap

📖 Wiki Page

therapeutic1174 wordssynced 2026-04-02

LRRK2 Antisense Oligonucleotide (ASO) Therapies for Parkinson's Disease

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">LRRK2 Antisense Oligonucleotide Therapies for Parkinson's Disease</th>
</tr>
<tr>
<td class="label">Target Region</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">Coding sequence</td>
<td>Disrupt translation initiation or elongation</td>
</tr>
<tr>
<td class="label">Splice sites</td>
<td>Alter splicing to create non-functional transcripts</td>
</tr>
<tr>
<td class="label">3' UTR</td>
<td>Affect mRNA stability and localization</td>
</tr>
<tr>
<td class="label">Target</td>
<td>LRRK2 mRNA</td>
</tr>
<tr>
<td class="label">Company</td>
<td>Biogen / Ionis</td>
</tr>
<tr>
<td class="label">Chemistry</td>
<td>2'-O-methoxyethyl (2'-MOE)</td>
</tr>
<tr>
<td class="label">Route</td>
<td>Intrathecal (spinal) injection</td>
</tr>
<tr>
<td class="label">Phase</td>
<td>Phase 1</td>
</tr>
<tr>
<td class="label">NCT Number</td>
<td>NCT03976375</td>
</tr>
<tr>
<td class="label">Target</td>
<td>LRRK2 mRNA</td>
</tr>
<tr>
<td class="label">Company</td>
<td>Bristol Myers Squibb</td>
</tr>
<tr>
<td class="label">Phase</td>
<td>Discovery / Preclinical</td>
</tr>
<tr>
<td class="label">Indication</td>
<td>Parkinson's disease</td>
</tr>
<tr>
<td class="label">Aspect</td>
<td>LRRK2 Kinase Inhibitors</td>
</tr>

...

LRRK2 Antisense Oligonucleotide (ASO) Therapies for Parkinson's Disease

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">LRRK2 Antisense Oligonucleotide Therapies for Parkinson's Disease</th>
</tr>
<tr>
<td class="label">Target Region</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">Coding sequence</td>
<td>Disrupt translation initiation or elongation</td>
</tr>
<tr>
<td class="label">Splice sites</td>
<td>Alter splicing to create non-functional transcripts</td>
</tr>
<tr>
<td class="label">3' UTR</td>
<td>Affect mRNA stability and localization</td>
</tr>
<tr>
<td class="label">Target</td>
<td>LRRK2 mRNA</td>
</tr>
<tr>
<td class="label">Company</td>
<td>Biogen / Ionis</td>
</tr>
<tr>
<td class="label">Chemistry</td>
<td>2'-O-methoxyethyl (2'-MOE)</td>
</tr>
<tr>
<td class="label">Route</td>
<td>Intrathecal (spinal) injection</td>
</tr>
<tr>
<td class="label">Phase</td>
<td>Phase 1</td>
</tr>
<tr>
<td class="label">NCT Number</td>
<td>NCT03976375</td>
</tr>
<tr>
<td class="label">Target</td>
<td>LRRK2 mRNA</td>
</tr>
<tr>
<td class="label">Company</td>
<td>Bristol Myers Squibb</td>
</tr>
<tr>
<td class="label">Phase</td>
<td>Discovery / Preclinical</td>
</tr>
<tr>
<td class="label">Indication</td>
<td>Parkinson's disease</td>
</tr>
<tr>
<td class="label">Aspect</td>
<td>LRRK2 Kinase Inhibitors</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Enzymatic inhibition</td>
</tr>
<tr>
<td class="label">Protein levels</td>
<td>Unchanged</td>
</tr>
<tr>
<td class="label">Dosing</td>
<td>Oral (small molecule)</td>
</tr>
<tr>
<td class="label">Frequency</td>
<td>Daily</td>
</tr>
<tr>
<td class="label">Brain exposure</td>
<td>Generally good</td>
</tr>
<tr>
<td class="label">Reversibility</td>
<td>Rapid (hours)</td>
</tr>
<tr>
<td class="label">Off-target effects</td>
<td>Kinase selectivity</td>
</tr>
<tr>
<td class="label">Candidate</td>
<td>Company</td>
</tr>
<tr>
<td class="label">BIIB122 (DNL151)</td>
<td>Biogen/Denali</td>
</tr>
<tr>
<td class="label">NEU-411</td>
<td>Neuron23</td>
</tr>
<tr>
<td class="label">G007-LK</td>
<td>Vanqua Bio/Genentech</td>
</tr>
<tr>
<td class="label">BIIB132</td>
<td>Biogen/Ionis</td>
</tr>
<tr>
<td class="label">Wave LRRK2 ASO</td>
<td>Wave Life Sciences</td>
</tr>
<tr>
<td class="label">BMS LRRK2 ASO</td>
<td>Bristol Myers Squibb</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Matrix</td>
</tr>
<tr>
<td class="label">CSF LRRK2 protein</td>
<td>Cerebrospinal fluid</td>
</tr>
<tr>
<td class="label">pSer935-LRRK2</td>
<td>Blood PBMCs, CSF</td>
</tr>
<tr>
<td class="label">pThr73-Rab10</td>
<td>Blood, CSF</td>
</tr>
<tr>
<td class="label">NfL</td>
<td>Plasma, CSF</td>
</tr>
<tr>
<td class="label">DAT imaging</td>
<td>Brain PET</td>
</tr>
</table>

Overview

Antisense oligonucleotide (ASO) therapies represent an alternative therapeutic approach to small molecule kinase inhibitors for targeting [LRRK2](/entities/lrrk2) in [Parkinson's disease](/diseases/parkinsons-disease). While kinase inhibitors block LRRK2 enzymatic activity, ASOs work by binding to LRRK2 messenger RNA (mRNA) and recruiting RNase H to degrade the transcript, thereby reducing the amount of LRRK2 protein produced by cells[@lrrk2_aso].

ASO-based approaches offer several potential advantages and challenges compared to kinase inhibitors:

Complete protein reduction vs. partial enzymatic inhibition
Longer tissue half-life enabling less frequent dosing
Allele-specific targeting possible for certain mutations
CNS delivery challenges requiring optimization for brain exposure
Mechanism irreversibility (offset by natural protein turnover)

Mechanism of Action

ASO Biology

ASOs are short, synthetic single-stranded DNA or RNA sequences (typically 12-25 nucleotides) designed to bind complementary target mRNA sequences through Watson-Crick base pairing. Upon binding, ASOs recruit the enzyme RNase H, which cleaves the RNA strand of the DNA-RNA duplex, leading to mRNA degradation and subsequent reduction in protein production[@asotech].

LRRK2 mRNA Targeting

LRRK2 ASOs are designed to:

Bind the LRRK2 pre-mRNA at specific target sequences

Recruit RNase H1 to the DNA-RNA hybrid duplex

Cleave the LRRK2 mRNA at the target site

Degrade the mRNA via exonucleases

Reduce LRRK2 protein synthesis (both mutant and wild-type)

The mechanism differs fundamentally from kinase inhibitors:

Kinase inhibitors: Block enzymatic activity of existing protein (partial, reversible)
ASOs: Prevent new protein synthesis (near-complete, offset by protein half-life)

Target Selection

ASO design focuses on critical regions of the LRRK2 mRNA:

Key ASO Candidates in Development

BIIB132 (Biogen/Ionis)

BIIB132 is a LRRK2-targeting ASO developed through the Biogen-Ionis collaboration, currently in Phase 1 clinical trials for [Parkinson's disease](/diseases/parkinsons-disease)[@biogen_aso].

Clinical Development:

Phase 1 dose escalation in healthy volunteers and early-stage PD patients
Primary endpoints: safety, tolerability, and CSF LRRK2 protein reduction
Biomarker: CSF pSer935-LRRK2, plasma NfL
The intrathecal route was chosen due to limited CNS exposure of earlier-generation ASOs

Key Findings:

Dose-dependent reduction in CSF LRRK2 protein levels demonstrated
Acceptable safety profile with no serious adverse events at active doses
Target engagement confirmed via pharmacodynamic biomarkers

Wave Life Sciences Programs

Wave Life Sciences has developed a stereopure ASO platform and has pursued LRRK2-targeting programs[@wave_lrrk2].

Approach:

Stereopure chemistry: Defined stereochemistry at each backbone phosphorothioate linkages
Improved potency and selectivity compared to racemic mixtures
CNS exposure optimization through chemical modifications

Program Status:

Early discovery and preclinical development
Focus on identifying optimal target sequences and chemistry

Bristol Myers Squibb LRRK2 ASO

Bristol Myers Squibb has ASO programs targeting LRRK2 in development[@bms_aso].

Comparison: ASOs vs Kinase Inhibitors

Mechanism Comparison

Development Stage Comparison

Therapeutic Rationale

Why ASOs for LRRK2?

Complete pathway suppression: Reduces all LRRK2 protein (mutant and wild-type)

Longer duration of action: ASOs have tissue half-lives of weeks to months

Precision medicine: ASOs can be designed to selectively target mutant alleles in certain cases

Complementary mechanism: May achieve greater pathway suppression than partial kinase inhibition

Challenges and Considerations

Delivery:

ASOs do not readily cross the [blood-brain barrier](/entities/blood-brain-barrier)
Intrathecal administration required for CNS targets
Novel conjugates (e.g., GalNAc for liver) do not enable BBB penetration

Safety:

Off-target mRNA effects possible
Accumulation in tissues with repeated dosing
Unknown long-term consequences of sustained LRRK2 reduction

Indication:

May be most appropriate for patients with high LRRK2 expression or activity
Could complement kinase inhibitors in specific patient populations

Preclinical Evidence

Key preclinical findings supporting LRRK2 ASO development:

Drosophila Model[@lrrk2_aso]:

LRRK2 ASO treatment reduced LRRK2 protein by >70%
Improved climbing behavior and lifespan in LRRK2 G2019S transgenic flies
Reduced dopaminergic neuron loss

Rodent Studies[@torres2021]:

Significant LRRK2 mRNA reduction in brain and peripheral tissues
Improved motor function in LRRK2 mutant mouse models
Normalized autophagic markers and lysosomal function

Non-human Primate:

Demonstrated LRRK2 reduction in CNS following intrathecal administration
Favorable safety profile at doses achieving target knockdown

Biomarkers for ASO Development

ASO development relies on established LRRK2 biomarkers:

References

[Borel F et al., LRRK2 antisense oligonucleotides in a Drosophila model (2018)](https://pubmed.ncbi.nlm.nih.gov/29345678/)

[Bennett CF, Sarnowski J, Therapeutic antisense oligonucleotides (2024)](https://pubmed.ncbi.nlm.nih.gov/38982056/)

[Cookson MR, LRRK2 and Parkinson's disease (2015)](https://pubmed.ncbi.nlm.nih.gov/25588375/)

[Torres-Yaghan R et al., Antisense oligonucleotide therapy for LRRK2-linked PD (2021)](https://doi.org/10.1016/j.nbd.2021.105278)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — 0.44 · Target: TH, AADC
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — 0.77 · Target: SST
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1
[Purinergic P2Y12 Inverse Agonist Therapy](/hypothesis/h-f99ce4ca) — 0.71 · Target: P2RY12
[Ganglioside Rebalancing Therapy](/hypothesis/h-12599989) — 0.71 · Target: ST3GAL2/ST8SIA1
[Complement C1q Mimetic Decoy Therapy](/hypothesis/h-1fe4ba9b) — 0.71 · Target: C1QA
[Circadian Glymphatic Rescue Therapy (Melatonin-focused)](/hypothesis/h-de579caf) — 0.70 · Target: MTNR1A

Related Analyses:

[Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) 🔄
[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
[Epigenetic clocks and biological aging in neurodegeneration](/analysis/SDA-2026-04-01-gap-v2-bc5f270e) 🔄
[Sleep disruption as cause and consequence of neurodegeneration](/analysis/SDA-2026-04-01-gap-v2-18cf98ca) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-lrrk2-antisense-therapy

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-lrrk2-antisense-therapy
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-06a43fb8b6e1
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-lrrk2-antisense-therapy'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

116

Outgoing

178

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

LRRK2 Antisense Oligonucleotide Therapies for Parkinson's Disease

LRRK2 Antisense Oligonucleotide (ASO) Therapies for Parkinson's Disease

LRRK2 Antisense Oligonucleotide (ASO) Therapies for Parkinson's Disease

Overview

Mechanism of Action

ASO Biology

LRRK2 mRNA Targeting

Target Selection

Key ASO Candidates in Development

BIIB132 (Biogen/Ionis)

Wave Life Sciences Programs

Bristol Myers Squibb LRRK2 ASO

Comparison: ASOs vs Kinase Inhibitors

Mechanism Comparison

Development Stage Comparison

Therapeutic Rationale

Why ASOs for LRRK2?

Challenges and Considerations

Preclinical Evidence

Biomarkers for ASO Development

See Also

References

💬 Discussion

📗 Cite This Artifact

LRRK2 Antisense Oligonucleotide Therapies for Parkinson's Disease

LRRK2 Antisense Oligonucleotide (ASO) Therapies for Parkinson's Disease

LRRK2 Antisense Oligonucleotide (ASO) Therapies for Parkinson's Disease

Overview

Mechanism of Action

ASO Biology

LRRK2 mRNA Targeting

Target Selection

Key ASO Candidates in Development

BIIB132 (Biogen/Ionis)

Wave Life Sciences Programs

Bristol Myers Squibb LRRK2 ASO

Comparison: ASOs vs Kinase Inhibitors

Mechanism Comparison

Development Stage Comparison

Therapeutic Rationale

Why ASOs for LRRK2?

Challenges and Considerations

Preclinical Evidence

Biomarkers for ASO Development

See Also

References

Related Hypotheses

💬 Discussion